NDAINJECTIONINJECTABLEPriority Review
Approved
Aug 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
IFEX (ifosfamide) by Baxter is alkylating activity [moa]. First approved in 1987.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IFEX (ifosfamide) is an alkylating chemotherapy agent approved in 1987 for treating solid tumors and hematologic malignancies. It works by cross-linking DNA strands, disrupting cancer cell replication. The drug is administered intravenously and is often used in combination regimens for testicular cancer, lymphomas, and soft tissue sarcomas.
LOE Approaching
As LOE approaches, the brand team is likely in defensive posture with reduced headcount; career growth opportunities are limited unless positioned in generics or biosimilar transition planning.
Mechanism of Action
Alkylating Activity
Pharmacologic Class:
Alkylating Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
Started Mar 2024
6 enrolled
Soft Tissue SarcomaStsSarcoma,Soft Tissue
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Started Feb 2024
148 enrolled
LeiomyosarcomaLiposarcomaSynovial Sarcoma+8 more
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Started Oct 2023
30 enrolled
Ewing SarcomaOsteosarcomaSarcomas
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
Started Nov 2022
43 enrolled
Diffuse Large B-Cell Lymphoma (DLBCL)
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
Started Apr 2021
306 enrolled
Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Worked on IFEX at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.